Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (401-410 of 504) with videos related to

Pageof 51
Sort By:
Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 9, 2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategiesMaria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, et al.
Leukemia|June 1, 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretomeLis Winter, Lea Pawlowsky, Amelie Muth, et al.
Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.
Blood|March 7, 2014
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistanceRodrigo Jacamo, Ye Chen, Zhiqiang Wang, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Blood Advances|September 10, 2021
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibitionKaori Saito, Qi Zhang, Haeun Yang, et al.
Leukemia & Lymphoma|June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignanciesGeorgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Pageof 51

Showing results (401-410 of 504) with videos related to

Sort By:
Pageof 51
Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 9, 2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategiesMaria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, et al.
Leukemia|June 1, 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretomeLis Winter, Lea Pawlowsky, Amelie Muth, et al.
Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.
Blood|March 7, 2014
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistanceRodrigo Jacamo, Ye Chen, Zhiqiang Wang, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Blood Advances|September 10, 2021
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibitionKaori Saito, Qi Zhang, Haeun Yang, et al.
Leukemia & Lymphoma|June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignanciesGeorgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Pageof 51